A Study to Identify the Molecular Basis of Pulmonary Vascular Disease and to Discover Biological Measurements of the Disease and Therapeutic Responses

Overview

About this study

The purpose of this study is to identify the molecular basis of various forms of heart and lung disease, particularly those that have varying degrees of pulmonary hypertension, pulmonary vascular remodeling, and right ventricular dysfunction.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Ages > 18 years
Referred for right heart catheterization for
- Further evaluation of known PVD
- Risk of PVD due to established cardiac disease or pulmonary disease
Able to perform complete diagnostic testing listed subsequently
- Cardiac catheterization
- Echo
- Exercise test
- PFT's
- ECG
- Chest CT
- Quality of life questionnaires
- Ventilation/perfusion scan
- Cardiac MRI
- Body composition bioimpedance
- Sleep study
Signed informed consent to perform required testing for the protocol

Exclusion Criteria

Dialysis dependent renal function
In the clinician's opinion, too ill to perform the protocol testing
Pregnant or nursing

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Robert Frantz, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Robert Frantz, M.D.

Closed for enrollment

More information

Publications

PVDOMICS (Pulmonary Vascular Disease Phenomics) is a precision medicine initiative to characterize pulmonary vascular disease (PVD) using deep phenotyping. PVDOMICS tests the hypothesis that integration of clinical metrics with omic measures will enhance understanding of PVD and facilitate an updated PVD classification. Read More on PubMed
The NIH/NHLBI launched an initiative, “Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS)” that aims to augment the current PH classification based on shared biological features. PVDOMICS will enroll 1,500 participants with PH and disease and healthy comparators. Enrollees will undergo deep clinical phenotyping and blood will be acquired for comprehensive “omic” analyses that will focus on discovery of molecular-based subtypes of PVD through application of high dimensional model-based clustering methods. In addition to an updated, molecular classification of PVD, the phenomic data generated will be a rich resource to the broad community of heart and lung disease investigators. Read More on PubMed

Clinical Trials